California Public Employees Retirement System acquires 8,069 shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN)


California Public Employees Retirement System has increased its stake in shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVNGet a rating) by 7.4% in the first quarter, according to its latest filing with the Securities & Exchange Commission. The institutional investor held 117,458 shares of the company after purchasing an additional 8,069 shares during the quarter. The California Public Employees Retirement System held approximately 0.17% of Biohaven Pharmaceutical worth $13,927,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Prospera Financial Services Inc bought a new position in Biohaven Pharmaceutical in the first quarter worth $160,000. Victory Capital Management Inc. raised its position in Biohaven Pharmaceutical by 6.4% in Q1. Victory Capital Management Inc. now owns 2,564 shares of the company worth $229,000 after purchasing an additional 155 shares during the period. Commonwealth Equity Services LLC increased its position in Biohaven Pharmaceutical by 6.8% during the first quarter. Commonwealth Equity Services LLC now owns 6,253 shares of the company valued at $741,000 after purchasing 397 additional shares during the period. Banque Pictet & Cie SA increased its position in Biohaven Pharmaceutical by 4.0% in the first quarter. Banque Pictet & Cie SA now owns 16,400 shares of the company valued at $1,945,000 after purchasing an additional 636 shares in the last quarter. Finally, Envestnet Asset Management Inc. strengthened its position in Biohaven Pharmaceutical by 12.5% ​​in the 1st quarter. Envestnet Asset Management Inc. now owns 29,849 shares of the company valued at $3,539,000 after purchasing an additional 3,305 shares during the period. 88.03% of the shares are held by institutional investors.

Insider Buying and Selling at Biohaven Pharmaceutical

In other news, CAD George C. Clark sold 4,200 shares of the company in a transaction that took place on Tuesday, May 10. The shares were sold at an average price of $141.50, for a total transaction of $594,300.00. Following the completion of the transaction, the chief accounting officer now directly owns 4,065 shares of the company, valued at $575,197.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC website. Insiders of the company own 12.40% of the shares of the company.

Biohaven Pharmaceutical Price Performance

Biohaven Pharmaceutical Stock opened at $147.10 on Friday. Biohaven Pharmaceutical Holding Company Ltd. has a 12-month low of $79.01 and a 12-month high of $151.51. The company’s fifty-day simple moving average is $145.20 and its two-hundred-day simple moving average is $129.71.

Biohaven Pharmaceutical (NYSE: BHVNGet a rating) last released its quarterly earnings data on Tuesday, May 10. The company reported ($2.97) earnings per share for the quarter, missing analyst consensus estimates of ($2.52) by ($0.45). The company posted revenue of $318.85 million for the quarter, versus analyst estimates of $187.12 million. During the same period of the previous year, the company posted EPS ($4.21). Sell-side analysts expect Biohaven Pharmaceutical Holding Company Ltd. will show earnings per share of -10.51 for the current year.

Analyst upgrades and downgrades

A number of brokerages have recently released reports on BHVN. Cantor Fitzgerald downgraded Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a Wednesday, May 11 report. HC Wainwright downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a Wednesday, May 11 report. Piper Sandler cut her price target on Biohaven Pharmaceutical shares from $156.00 to $149.00 and gave the stock an “na” rating in a Tuesday, May 24 research report. Finally, SVB Leerink downgraded shares of Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and set a price target of $150.00 for the company. in a report from Wednesday, May 11. Five research analysts gave the stock a hold rating and two gave the company a buy rating. According to MarketBeat, Biohaven Pharmaceutical currently has an average rating of “Hold” and an average target price of $158.25.

About Biohaven Pharmaceutical

(Get a rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

See also

Want to see what other hedge funds hold BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVNGet a rating).

Institutional ownership by quarter for Biohaven Pharmaceutical (NYSE: BHVN)



Get news and reviews for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.